Longevity Health (NASDAQ:XAGE) & Perspective Therapeutics (NASDAQ:CATX) Head-To-Head Analysis

Perspective Therapeutics (NASDAQ:CATX) and Longevity Health (NASDAQ:XAGE) are both small-cap manufacturing companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, earnings, analyst recommendations, profitability, institutional ownership, valuation and risk.

Valuation and Earnings

This table compares Perspective Therapeutics and Longevity Health”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Perspective Therapeutics	N/A	N/A	N/A	($0.90)	-2.62
Longevity Health	$1.05 million	0.63	-$10.37 million	($3.91)	-0.09

Perspective Therapeutics has higher earnings, but lower revenue than Longevity Health. Perspective Therapeutics is trading at a lower price-to-earnings ratio than Longevity Health, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Perspective Therapeutics and Longevity Health’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Perspective Therapeutics	N/A	N/A	N/A
Longevity Health	-682.67%	N/A	-261.90%

Analyst Ratings

This is a breakdown of current recommendations for Perspective Therapeutics and Longevity Health, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Perspective Therapeutics	0	0	3	0	3.00
Longevity Health	0	0	0	0	0.00

Perspective Therapeutics currently has a consensus target price of $10.00, indicating a potential upside of 323.73%. Given Perspective Therapeutics’ stronger consensus rating and higher probable upside, research analysts clearly believe Perspective Therapeutics is more favorable than Longevity Health.

Risk and Volatility

Perspective Therapeutics has a beta of 1.22, indicating that its share price is 22% more volatile than the S&P 500. Comparatively, Longevity Health has a beta of 0.34, indicating that its share price is 66% less volatile than the S&P 500.

Institutional & Insider Ownership

54.7% of Perspective Therapeutics shares are held by institutional investors. Comparatively, 24.2% of Longevity Health shares are held by institutional investors. 3.7% of Perspective Therapeutics shares are held by company insiders. Comparatively, 29.0% of Longevity Health shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Perspective Therapeutics beats Longevity Health on 8 of the 11 factors compared between the two stocks.

About Perspective Therapeutics

Isoray, Inc., through its subsidiary, IsoRay Medical, Inc., develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company offers CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers. It sells its products to facilities or physician practices that utilize various surgical facilities. Isoray, Inc. was founded in 1998 and is based in Richland, Washington.

About Longevity Health

Carmell Therapeutics Corporation focuses on the development of plasma-based bioactive material (PBM) to stimulate tissue repair or growth after injury, disease, and aging. Its lead product candidate is CT-101 bone healing accelerant for tibia fracture healing, foot/ankle fusion, spinal fusion, dental bone graft substitute, and bone void filler; and tissue healing accelerant for androgenetic alopecia and chronic wound healing. The company was founded in 2008 and is based in Pittsburgh, Pennsylvania.